An improved knowledge of the mechanisms involved in colorectal carcinogenesis and tumor progression has allowed the development of biological agents with targeted actions, as inhibitors of angiogenesis, EGFR-targeted therapy, and immunotherapy [5]. The gene discussed is EGFR; the disease is neoplasm.